Results 131 to 140 of about 2,377 (150)

Computational Analysis of S1PR1 SNPs Reveals Drug Binding Modes Relevant to Multiple Sclerosis Treatment. [PDF]

Pharmaceutics
Kores K, Lešnik S, Bren U.
europepmc   +1 more source

Pharmacogenetics of siponimod: A systematic review [PDF]

Biomedicine and Pharmacotherapy, 2022
Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent) is the first oral treatment option for adult patients with secondary progressive multiple sclerosis.
Alba Antúnez-Rodríguez, Xando Díaz-Villamarín   +1 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Siponimod associated macular edema in a patient with multiple sclerosis

Neuroimmunology Reports, 2021
Sean Gratton
exaly  

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects

Clinical Therapeutics, 2020
Anne Gardin, Eric Legangneux
exaly  

The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study)

Journal of Clinical Medicine, 2023
Montserrat Bosch Ferrer, Irene Gómez-Estévez, Eva Montané   +2 more
exaly  

Top bar navigation

Frontiers in Pharmacology, 2022
exaly  

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics

European Journal of Clinical Pharmacology, 2017
Gian Camenisch, Yi Jin, Felix Huth
exaly